about
Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige miceTreatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infectionThe extra cytoplasmic function sigma factor sigma(E) is essential for Mycobacterium tuberculosis virulence in miceWhole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patientsRisk factors for tuberculosis in foreign-born people (FBP) in Italy: a systematic review and meta-analysisActivity of drug combinations against dormant Mycobacterium tuberculosisInfluence of Mycobacterium bovis bacillus Calmette Guérin on in vitro induction of CD1 molecules in human adherent mononuclear cellsInfection of human dendritic cells with a Mycobacterium tuberculosis sigE mutant stimulates production of high levels of interleukin-10 but low levels of CXCL10: impact on the T-cell responseTowards tuberculosis elimination: an action framework for low-incidence countriesIsolation of Nocardia asiatica from cutaneous ulcers of a human immunodeficiency virus-infected patient in Italy.IFN-beta improves BCG immunogenicity by acting on DC maturation.Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results.Targeting dormant bacilli to fight tuberculosis.Infection of human THP-1 cells with dormant Mycobacterium tuberculosis.Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.Beta-lactamase of Mycobacterium fortuitum: kinetics of production and relationship with resistance to beta-lactam antibiotics.Activity of drugs against dormant Mycobacterium tuberculosis.Drug-resistant tuberculosis in Naples, 2008-2013.Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system.Inhibition of HIV-1 replication in monocyte-derived macrophages by Mycobacterium tuberculosis.Cetyl-pyridinium chloride is useful for isolation of Mycobacterium tuberculosis from sputa subjected to long-term storage.Mycobacterium tuberculosis diverts alpha interferon-induced monocyte differentiation from dendritic cells into immunoprivileged macrophage-like host cellsActivity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.Expression of proinflammatory and regulatory cytokines via NF-κB and MAPK-dependent and IFN regulatory factor-3-independent mechanisms in human primary monocytes infected by Mycobacterium tuberculosis.Rifampin induces hydroxyl radical formation in Mycobacterium tuberculosisMetronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.Usefulness of the BACTEC MGIT 960 system for isolation of mycobacterium tuberculosis from sputa subjected to long-term storage.Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum.The Mycobacterium tuberculosis sigma factor sigmaB is required for full response to cell envelope stress and hypoxia in vitro, but it is dispensable for in vivo growth.Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient.Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis.GenoType MTBDRsl performance on clinical samples with diverse genetic background.Exposure of BALB/c mice to low doses of Mycobacterium avium increases resistance to a subsequent high-dose infection.Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000.The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice.Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients.
P50
Q28376599-56F84E1E-F089-4920-A33A-C131321B37A4Q28476640-968D20EE-0FE9-4FBF-9A32-0F17AAFD47A8Q28487009-CC5E588E-9326-4FE7-B98F-7DDA2D867E9AQ28536445-BCA111E6-C72E-4516-9136-0D8B604117E6Q28537863-62ED8E5B-CA4E-4D11-8B32-486FB2A2A8F9Q33876588-2C551771-2F38-45DA-9926-590765F45070Q34009687-05376BFC-A145-4695-A135-A0833CB8A94BQ34681342-642209F8-A9F9-41F0-95B5-39452C513471Q35344151-88AFFD6D-5F06-4749-9DF0-799FC33A1EB6Q35913884-51D2C9D3-8707-43CA-85FD-A257F2C16AE4Q37283820-14AF022B-95FF-41BF-A080-619D20E2AB56Q37410535-E3B69E83-98D5-4927-B2FC-C7AD38ACE8EEQ38173371-C74FDDCF-1A57-4A17-AEA5-764646709026Q39356278-A404CABB-CBAB-45A1-B221-8CBA7AC7FA48Q39730859-8923CF8D-F040-42BC-902F-B10B4AC9D6B2Q40048055-CF887C76-BA8C-4406-822A-6FDEEB6342B6Q40087297-4AA420BC-7F35-4F5E-A11A-58EE0A7E1F41Q40387866-0B4B4FC3-A319-4887-A561-7C4E113F35F5Q40414753-DAFC3D06-F20A-4ECB-8F33-B1C636936CFEQ40417948-3ADC8F7B-28D2-4E12-8373-C8B41F6110D0Q40591403-246E1320-745F-4AA0-8E00-D1D450A76FD1Q40770552-BEC9A75F-0B08-495C-88FE-E0DF9D910C0CQ41195683-206D0875-11EB-4BF3-A928-97DE5380D964Q41257028-5E285445-66D2-4F94-9FC6-D9FF02E4BE56Q41454109-47BF71E1-44C2-4B0D-AAAC-D0F87EA0DFEBQ41488141-C8C00459-60DD-4343-8EC7-8D864C8B3572Q41713635-39AAAD35-125D-480E-826D-38F1B400E04BQ41853471-B037D674-4412-4851-B87D-6C2EC26DFF4FQ41872308-71E5ED0E-993E-473D-B47B-13A79289FB95Q41901445-ED8E2C80-25C6-4619-8506-79648C32D696Q41945993-F1D93C4C-FAE8-4DC5-9997-C2F259EC837BQ42127991-BB3330CF-9C73-438C-8AF9-DC816E96BC6EQ42545993-3FA18CB1-95EC-433A-89B0-AD6D47E1EB4BQ42593454-8FB5CAB3-5B6F-41E1-AFD4-DAACD4DD4662Q42797817-EF874035-5290-44FD-BF17-7F4595E1D304Q43757490-93A30A02-85C4-494C-969B-26A5F4828670Q44238607-514731EC-BDAE-4E8C-BE7E-957F2896130DQ44304495-893EFD3E-A92E-43CF-8172-8B281B4DAF41Q44831422-19AF0C21-247A-430C-BE5C-E7A25941337DQ44988391-B4650EA6-BC90-4F6E-982C-E7DFE3F3518C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lanfranco Fattorini
@ast
Lanfranco Fattorini
@en
Lanfranco Fattorini
@es
Lanfranco Fattorini
@nl
type
label
Lanfranco Fattorini
@ast
Lanfranco Fattorini
@en
Lanfranco Fattorini
@es
Lanfranco Fattorini
@nl
prefLabel
Lanfranco Fattorini
@ast
Lanfranco Fattorini
@en
Lanfranco Fattorini
@es
Lanfranco Fattorini
@nl
P106
P1153
7004520484
P31
P496
0000-0003-1673-1804